GleamWall
中文EN

HLYK HealthLynked Corp

Services-Offices & Clinics of Doctors of Medicine · OTC · SEC CIK 1680139 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-52.0%
TTM net income YoY-4.5%
TTM EPS YoY1.5%
Revenue 3-yr CAGR-43.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-202.3%
Net margin-351.6%
FCF margin—
EBITDA margin-196.7%

Returns

ROE—
ROA-234.0%
ROIC (approx.)—
Asset turnover0.67x

Leverage & solvency

Liabilities / assets641.2%
Debt / equity—
Current ratio0.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-153.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$155,934$249,830$423,465$310,179$388,545$592,360$774,208$618,927
SG&A expense$435,920$517,489$847,281$453,610$500,736$451,755$629,415$546,196
Operating income-$535,016-$538,776-$700,813-$530,894-$529,586-$435,385-$617,389-$748,774
Interest expense$755$756——$42,453$42,153——
Pretax income———————-$1.23M
Net income-$888,892-$819,705-$1.62M-$676,477-$851,800-$701,038-$1.05M-$1.23M
EBITDA-$533,245-$528,547-$674,773-$504,440-$509,431-$408,147-$589,365-$720,338
EPS (basic)-0.29-0.28-0.56—-0.30-0.25-0.37—
EPS (diluted)-0.29-0.28-0.56—-0.30-0.25-0.37—
Weighted avg. shares (diluted)3.10M2.94M2.90M—2.83M2.82M2.82M—
Balance sheet
Cash & equivalents$16,594$12,844$23,973$37,136$10,911$20,201$22,270$76,241
Inventory$14,157$18,300$18,471$17,962$31,977$27,589$32,259$44,686
Current assets$1.54M$1.54M$1.54M$1.55M$1.54M$1.56M$1.57M$1.64M
PP&E, net$36,665$38,437$48,665$74,705$101,159$121,314$148,552$176,576
Total assets$1.58M$1.59M$1.63M$1.70M$1.85M$1.85M$2.06M$2.22M
Current liabilities$2.95M$8.90M$8.20M$7.01M$6.74M$6.13M$5.60M$4.69M
Total liabilities$10.10M$9.35M$8.65M$7.46M$7.20M$6.60M$6.19M$5.35M
Shareholders' equity-$8.53M-$7.75M-$7.02M-$5.76M-$5.43M-$4.75M-$4.14M-$3.13M
Shares outstanding2.97M2.95M2.94M2.88M2.85M281.95M281.95M2.82M
Cash flow statement
Operating cash flow-$392,401-$350,133-$221,976-$419,430-$444,291-$417,536-$432,553-$743,602
Capital expenditure———————$0
Free cash flow———————-$743,602
Investing cash flow———————$425,000
Financing cash flow$396,151$339,004$208,813$320,655$435,001$415,467$378,582$379,885
Depreciation & amortization$1,771$10,229$26,040$26,454$20,155$27,238$28,024$28,436
Stock-based compensation$75,599$88,237$297,522$93,216$4,694$5,267$7,126$18,294

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.